Cancer Control最新文献

{"title":"Validation of a Chemotherapy Toxicity Prediction Model in Older Adults With Cancer in Taiwan.","authors":"Chieh-Ying Chang, Yu-Shin Hung, Ming-Chung Kuo, Wen-Chi Chou","doi":"10.1177/10732748251347902","DOIUrl":"10.1177/10732748251347902","url":null,"abstract":"<p><p>IntroductionThe Cancer and Aging Research Group (CARG) model predicts chemotherapy-related toxicities in older patients; however, its applicability has not been validated in Taiwanese patients. This study aims to validate the CARG model in older Taiwanese patients with solid tumors.MethodsPatients (N = 258) aged ≥65 years with solid tumors from a single medical center, slated for first-line chemotherapy, were recruited between 2018 and 2021, with follow-up until December 31, 2022. Patients were categorized into low- (N = 85), medium- (N = 117), and high- (N = 56) risk based on CARG. Validation of CARG involved receiver operating characteristic (ROC) curves. Individual CARG variables were analyzed using univariate analysis for their impact on toxicities and survival.ResultsToxicities of grades ≥3 were 38.8%, 44.4%, and 67.9% (<i>P</i> = .001) in the three ascending risk groups, and there were significant differences in both hematological (<i>P</i> = .002) and non-hematological (<i>P</i> < .001) toxicities. ROC was 0.631 (95% CI: 0.562-0.700), indicating satisfactory discrimination. One-year overall survival rates were 88.7%, 79.7%, and 63.8%, respectively, in ascending-risk groups, with high-risk groups showing decreased survival (<i>P</i> = .002). In the multivariate analysis, decreased hemoglobin, history of falls, and inability to walk one block remained significantly associated with toxicity. For overall survival, the inability to take medications was the only independent predictor.ConclusionThis prognostic study validated the CARG model in a heterogeneous solid tumor cohort in Taiwan. In addition to predicting both hematological and non-hematological toxicities, CARG could offer insights into patient survival among older individuals with cancer.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347902"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cancer Burden on Patients and Their Families in a Resource-Restricted Country: A Cross-Sectional Survey Study From Georgia.","authors":"Tamar Kakhniashvili, Ivane Kiladze, Nino Okribelashvili","doi":"10.1177/10732748251359407","DOIUrl":"10.1177/10732748251359407","url":null,"abstract":"<p><p>IntroductionPatients and their families face financial difficulties during cancer care. This study aims to assess patients' unmet needs and financial challenges during diagnosis and treatment, representing the first research in the Republic of Georgia to address these economic issues.MethodsIn this multicenter, retrospective, observational study, a questionnaire was distributed, and clinical data were collected from 181 patients undergoing active cancer treatment across 7 tertiary hospitals. The primary outcomes of the study were the patient-reported experience of cancer-related financial burden on the family and the frequency of debt taken for cancer diagnosis or treatment.ResultsThe median age was 63, with 55.2% being female. Most patients (135/181, or 74.5%) reported a \"moderate\" or \"heavy\" economic burden from cancer care. During diagnosis and treatment, 129 patients (71.3%) incurred out-of-pocket costs, and 44.2% took out loans for care, with 10 patients (5.6%) doing so multiple times. The most common reason for debt (76/181) was to cover diagnostic procedures. Only 57 patients (31.5%) reported stable employment at the time of the survey, and among the 149 employed/self-employed, 50 (33.5%) experienced work-related issues due to cancer. Younger patients (≤65) had a tendency to take on debt more frequently (49.5%) compared to older (>65) patients (37%), but this difference was not statistically significant (<i>P</i>-value .097).ConclusionCancer care in Georgia imposes a heavy financial burden, with significant out-of-pocket costs for most patients. Improved access to financial assistance is required to better avoid potential inequities.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251359407"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Duloxetine With Mirogabalin for Treating Taxane-Induced Peripheral Neuropathy in Advanced Lung Cancer.","authors":"Yasuhiro Nakajima, Kozo Kuribayashi, Akio Tada, Akichika Nagano, Toshiyuki Minami, Arihiko Kanehiro, Takashi Kijima","doi":"10.1177/10732748251353327","DOIUrl":"10.1177/10732748251353327","url":null,"abstract":"<p><p>IntroductionTaxane-based cytotoxic anticancer drugs are a cornerstone of advanced lung cancer chemotherapy; however, they often result in chemotherapy-induced peripheral neuropathy (CIPN). Along with prolonged recovery, CIPN may cause irreversible damage. Consequently, dose reduction or discontinuation is justified, potentially impacting therapeutic efficacy. With no established treatment for CIPN, low-dose duloxetine is generally used as a supportive drug. However, studies have shown the potential effect of mirogabalin on CIPN. Therefore, at our hospital, patients with advanced lung cancer experiencing CIPN during taxane-based first-line therapy received low-dose duloxetine, and were subsequently treated with mirogabalin.MethodsIn this study, we conducted a retrospective observational cohort study of the impact of mirogabalin administration on 14 advanced lung cancer patients when duloxetine alone was deemed insufficient. The median age was 71 years (52-89 years), with 9 male and 5 female patients. The Numerical Rating Scale (NRS) was utilized to evaluate outcomes, and Wilcoxon's signed rank-sum test was used in statistical analysis.ResultsThe median Numerical Rating Scale (NRS) score decreased from 5.5 (interquartile range [IQR]: 4.5-7.0) before to 4.0 (IQR: 3.0-5.0) after mirogabalin administration (<i>P</i> = 0.041), indicating significant pain reduction.ConclusionThe addition of mirogabalin to duloxetine shows promise in alleviating CIPN in advanced lung cancer patients treated with taxane anticancer agents. These findings warrant further investigation and consideration for their integration into clinical practice for managing CIPN.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353327"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, Regional, and National Burden and Trends of Soft Tissue and Other Extraosseous Sarcomas From 1990 to 2021.","authors":"Rui Zhu, Ziyuan Shen, Haijuan Zhu, Jisen Zhang, Xing Xing, Shengyou Wang, Jialiu Fang","doi":"10.1177/10732748251355841","DOIUrl":"10.1177/10732748251355841","url":null,"abstract":"<p><p><b>Introduction:</b> Soft Tissue and Other Extraosseous Sarcomas (STOES) represent a rare and heterogeneous group of malignancies with significant clinical challenges due to their complexity and aggressiveness. Despite their low prevalence, the global impact of STOES is substantial, necessitating a detailed examination of their epidemiology and disease burden. <b>Methods:</b> This comprehensive analysis utilized data from the Global Health Data Exchange (GHDx) covering the years 1990 to 2021. We assessed the incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALYs) for STOES, categorized by location, sex, and socio-demographic indices. Statistical methods included Estimated Annual Percentage Change (EAPC), Spearman correlation analysis, and Bayesian age-period-cohort modeling. <b>Findings:</b> In 2021, STOES cases reached a global prevalence of 480,473, a significant increase from 1990. High Socio-Demographic Index (SDI) regions exhibited the highest age-standardized incidence and prevalence rates (ASIR and ASPR) at 2.05 and 10.61 per 100,000 population, respectively. Notably, significant increases were also observed in Central Asia, Central Europe, and Southern Sub-Saharan Africa. Males consistently showed higher disease rates than females. The decomposition analysis highlighted population growth and aging as primary drivers of the observed trends. Forecasting suggests a decline in the global STOES burden by 2030, though disparities will persist, particularly among males. <b>Conclusion:</b> The study reveals critical geographic and demographic disparities in the burden of STOES, underscoring the ongoing higher risk among males and in certain global regions. Despite projected declines in overall disease burden by 2030, substantial disparities are expected to persist, necessitating targeted public health interventions and robust policies to effectively mitigate these differences and enhance global health outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251355841"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.","authors":"Haibo Wang, Tao Lu, Xinlong Zheng, Kan Jiang, Longfeng Zhang, Xiaobin Zheng, Qian Miao, Shiwen Wu, Zihua Zou, Shanshan Yang, Yujing Li, Sihui Chen, Yiquan Xu, Gen Lin","doi":"10.1177/10732748241311223","DOIUrl":"10.1177/10732748241311223","url":null,"abstract":"<p><strong>Background: </strong>The proportion and impact of minimal pleural effusion (PE) on prognosis remain blurred in operable non-small cell lung cancer (NSCLC) patients who reported minimal PE on imaging.</p><p><strong>Methods: </strong>Clinical and prognostic data of operable NSCLC patients who presented no distant metastasis, no direct pleural invasion, but minimal PE on preoperative imaging were retrospectively analyzed. The patients were divided into surgical (81 cases) and non-surgical (10 cases) cohorts. Potential or suspected malignant PE or pleural metastases were confirmed by surgery. The overall survival (OS) was analyzed by Kaplan-Meier curve and prognostic factors by multivariate Cox regression.</p><p><strong>Results: </strong>The surgical cohort reported no pleural invasion on preoperative imaging and no pleural metastases by postoperative pathology, with an overall median disease-free survival of 36.7 (28.6, 44.7) months and a median OS of 59.8 (45.7, 73.2) months, with the latter significantly longer in the surgical cohort than in the non-surgical cohort (59.8 months vs 20.37 months, <i>P</i> < 0.001). Multivariate analysis indicated surgical treatment as an independent prognostic factor for OS.</p><p><strong>Conclusion: </strong>Malignant PE is rare in operable NSCLC patients who report the presence of minimal PE but no distant metastasis or direct pleural invasion on preoperative imaging. Surgery may be the preferred treatment for these patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241311223"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter re: Blood-Based Multi-Cancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening.","authors":"K P Ameya, Durairaj Sekar","doi":"10.1177/10732748251317688","DOIUrl":"10.1177/10732748251317688","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251317688"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Osteoporosis in Elderly Cancer Patients Using the Modified Glasgow Prognostic Index.","authors":"Muge Ustuner, Sabin Goktas Aydin, Ahmet Aydin, Bahar Ozguzel, Eda Nur Duran, Elif Kadioglu Yeniyurt, Elif Senocak Tasci, Bahar Bayramova","doi":"10.1177/10732748251337601","DOIUrl":"https://doi.org/10.1177/10732748251337601","url":null,"abstract":"<p><p>IntroductionOsteoporosis increases fracture risk and mortality, and cancer treatments worsen bone loss. Although mGPS is a common inflammatory-nutritional marker in oncology, its role in predicting osteoporosis is unknown.MethodsThis cross-sectional retrospective study analyzed 93 cancer patients aged ≥50 who underwent dual-energy X-ray absorptiometry (DXA) scans within a year of the first chemotherapy allocation. The results were categorized into groups regarding T-score as normal (T ≥ -1.0), osteopenia (-2.5 < T < -1.0), and osteoporosis (T ≤ -2). Patients were categorized based on mGPS and body mass index (BMI), and regression analysis was performed to identify predictors of osteoporosis in the lumbar spine, femur neck, and total femur.ResultsAmong the patients, 61.3% were female, the median age was 61 years, 41.9% had osteoporosis in the lumbar spine, and 49.5% had osteopenia in the femoral neck. A significant association was observed between BMI and osteoporosis, with higher BMI linked to lower osteoporosis prevalence, particularly in the femur regions (<i>P</i> < .03). There were no significant associations between bone density in the lumbar spine/femoral neck/total femur and age, gender, disease stage, type of chemotherapy, or BMI (all <i>P</i> values >.05). A significant association between mGPS and bone density was observed in the lumbar spine (<i>P</i> = .001) and femur total (<i>P</i> < .001). In the lumbar spine, patients with an mGPS score of 0 had the highest proportion of normal bone density (71.4%), while those with an mGPS score of 2 had a higher prevalence of osteoporosis (55.6%) (<i>P</i> = .001). In the femur total, 46.7% of patients with an mGPS score of 2 were classified with osteoporosis, compared to only 8.5% of those with an mGPS score of 0 (<i>P</i> < 001). Patients with an mGPS score of 2 were over six times more likely to have osteoporosis in the lumbar spine (OR = 6.25,<i>P</i> = 0.027). In the femur total, an mGPS score of 2 also significantly predicted osteoporosis (OR = 5.472, <i>P</i> = .013).ConclusionmGPS is a cost-effective and reliable tool for predicting osteoporosis in elderly cancer patients, enabling early interventions. Integrating it into routine assessments could enhance patient outcomes by addressing osteoporosis risk.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251337601"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and Challenges in Cervical Cancer: From Molecular Mechanisms and Global Epidemiology to Innovative Therapies and Prevention Strategies.","authors":"Raiyan Ul Hakim, Tasbir Amin, S M Bakhtiar Ul Islam","doi":"10.1177/10732748251336415","DOIUrl":"https://doi.org/10.1177/10732748251336415","url":null,"abstract":"<p><p>BackgroundIn the global scenario of public health, cervical cancer poses a major threat with high mortality rates, especially in women. New incidence cases and prevalence vary across different regions, as recently shown by GLOBOCAN data. The development of cervical cancer is primarily due to persistent infection by high-risk genotypes of human papillomavirus (HPV), which is a multifaceted process that is influenced by genetic, environmental, and lifestyle factors.PurposeThe goal of this study is to thoroughly investigate cervical cancer, including its etiology, molecular mechanisms, progression, diagnosis strategies, and current therapies. This review further highlights the transformative power of HPV vaccination and screening programs in curbing the disease's burden and potentially promising novel approaches like immunotherapy and targeted therapy.Research DesignThis is a narrative review article that summarizes previous literatures regarding cervical cancer in terms of molecular mechanism, etiology, clinical developments, and prevention.Study SampleThe review encompassed studies from diverse sources, including experimental, observational, and clinical research published between 1992 and 2025.Data Collection and/or AnalysisData were collected through comprehensive literature searches using databases such as PubMed, Scopus, and the Cochrane Library with defined inclusion and exclusion criteria.ResultsNonetheless, there are gaps in research and controversies regarding vaccine coverage, screening practices, and treatment accessibility for poor populations. Precision medicine trends are emerging along with new biomarkers for early detection and personalized treatment, which also form part of this discussion. Key findings include the critical role of prevention measures in controlling the global impact of cervical cancer.ConclusionsThe paper synthesizes the existing knowledge and identifies gaps that require further research, which is significant in augmenting prevention, diagnosis, and treatment of cervical cancer towards addressing its public health implications worldwide.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251336415"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain as an Adverse Event During Chemotherapy in Children with Acute Lymphoblastic Leukemia: A Cross-Sectional Nationwide Study.","authors":"Fernanda Machado Silva-Rodrigues, Pamela S Hinds, Carlos Alberto Scrideli, Silvia Regina Brandalise, Maria Alessandra Silva Salgado, Lucila Castanheira Nascimento","doi":"10.1177/10732748251341522","DOIUrl":"10.1177/10732748251341522","url":null,"abstract":"<p><p>IntroductionPain is a common adverse event of chemotherapy in pediatric oncology patients. Understanding pain's impact on these patients is essential for improving their quality of life and treatment outcomes. This short communication aims to describe the characteristics of pain in children with Acute Lymphoblastic Leukemia (ALL) and to explore its interactions with hospitalization duration and relapse, considering variables such as age, gender, and risk level.MethodsThis retrospective study analyzed data from 610 observations of pediatric patients with ALL treated under the Brazilian GBTLI-99 protocol. Pain was recorded according to CTCAE criteria. Statistical analyses, including Chi-square, Mann-Whitney, Poisson, and logistic regression models, were applied to explore associations between pain, hospitalization length, relapse, and other variables.ResultsOur results indicated that patients who presented with pain experienced longer hospitalization lengths. No significant difference in the presence of pain in female or male pediatric patients was observed.ConclusionThis study is a first step towards treating pain as a limiting event that compromises the quality of life and response to treatment in Brazilian pediatric cancer patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251341522"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of Network Meta-Analyses on the Efficacy of Chemopreventive Agents on Colorectal Adenomas and Cancer.","authors":"Yibing Ruan, Chantelle Carbonell, Karen Brown, Robert J Hilsden, Darren R Brenner","doi":"10.1177/10732748251344481","DOIUrl":"10.1177/10732748251344481","url":null,"abstract":"<p><p>BackgroundColorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Colorectal adenomas (CRAs) are a crucial precursor for CRC and a target for preventive strategies. Recent network meta-analyses (NMAs) of randomized controlled trials (RCTs) suggest that chemopreventive agents (CPAs) are associated with reductions in CRC incidence. However, the quality of this evidence is low due to significant variability in the methods and types of studies assessed.PurposeOur study reviewed the efficacy and safety of CPAs on CRAs or CRCs evaluated in NMAs of RCTs and assessed the quality of all published NMAs on CPAs.Research DesignWe searched PubMed, Embase, and Cochrane Library for studies published from inception to July 29, 2024. We included all NMAs assessing the efficacy and safety of CPAs on CRC in both average-risk (general population) and high-risk (previous history of adenoma/CRC) populations. ResultsNine NMAs comparing 15 different interventions were included. Aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib were the most studied. Aspirin demonstrated efficacy against the development of any CRA and low-dose aspirin was consistently more protective than high-dose aspirin. However, the effect of aspirin against advanced CRA was not statistically significant. Concerns for long-term aspirin use included an increased risk of gastrointestinal bleeding and ulceration, but when evaluating all serious adverse events (SAEs), aspirin users did not have an increased risk compared to controls. Non-aspirin NSAIDs showed better efficacy against advanced CRA. However, the use of non-aspirin NSAIDs such as celecoxib was associated with significantly increased risk of SAEs, particularly cardiovascular disease events.ConclusionsConsidering the balance of efficacy and safety, low-dose aspirin is currently the best option for chemoprevention of CRA/CRC. Future research is needed to better characterize the patient subgroups that benefit most and to develop new, more effective CPAs.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251344481"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}